Introduction
============

Concurrent chemoradiotherapy (CCRT) is the preferred treatment for patients with advanced-stage non-small-cell lung cancer (NSCLC). Although CCRT brings survival benefit compared with sequential chemoradiation or radiotherapy (RT) alone, the risk of post-therapy toxicity as acute esophagitis (AE) may increase.[@b1-ott-11-6167] AE often occurs 2 weeks after the start of RT, including retrosternal pain, dysphagia, and odynophagia. Severe AE may require analgesics and parenteral nutrition and can even lead to treatment interruptions, which may reduce the quality of life of the patients and lower the chance of local tumor control.[@b2-ott-11-6167],[@b3-ott-11-6167]

Previous studies have attempted to define clinical and dosimetric predictors of radiation-induced esophagitis. Factors found to correlate with AE include CCRT,[@b4-ott-11-6167],[@b5-ott-11-6167] lymphatic status,[@b6-ott-11-6167],[@b7-ott-11-6167] hyperfractionated RT (1.6 Gy/fraction twice daily),[@b8-ott-11-6167] esophageal length,[@b9-ott-11-6167] molecular markers,[@b10-ott-11-6167] and a number of dosimetric parameters.[@b11-ott-11-6167]--[@b16-ott-11-6167] However, the clinical applicability of these studies' findings remains restricted because of their various study populations, different RT techniques, and different end points. In addition, there are differences between the classification systems of the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria[@b17-ott-11-6167] and the Common Toxicity Criteria for Adverse Events (CTCAE) version. Most studies focus on three-dimensional conformal radiotherapy (3D-CRT), and the impact of intensity-modulated radiotherapy (IMRT) on AE is less reported. Research has shown that 3D-CRT toxicity prediction models are not suitable for predicting toxicity after IMRT.[@b18-ott-11-6167],[@b19-ott-11-6167]

New research has shown that different parts of the esophagus have different sensitivities to AE.[@b20-ott-11-6167] However, the dosimetric predictors for AE in current studies are for the whole esophagus. In fact, most radiation areas for NSCLC cover only part of the esophagus. IMRT has advantages in reducing the exposure of organs at risk (OARs).[@b21-ott-11-6167]--[@b23-ott-11-6167] However, it is difficult to constraint the dose of the whole esophagus and OARs together in some cases because of the anatomical positional relationship between OARs and tumors. Therefore, position factors should be regarded with care in the prediction of AE.

The objective of this study was to estimate the relation between AE and clinical, dosimetric, and position factors in patients with local regional advanced NSCLC receiving intensity-modulated (chemo)radiotherapy.

Materials and methods
=====================

Patients
--------

In this retrospective study, we assessed a cohort of 193 consecutive patients who had undergone intensity-modulated (chemo)radiotherapy for stages IIa--IIIc NSCLC from March 2015 to December 2017 at a single center. This investigation was approved by the local institutional review board. The inclusion criteria histologically or cytologically confirmed NSCLC, with full dose--volume histogram (DVH) and clinical data available for evaluation. The exclusion criteria were postoperative radiation therapy for lung cancer, previous irradiation of chest, history of esophageal surgery, and esophageal cancer.

Radiation simulation, planning, and delivery
--------------------------------------------

Patients were immobilized in the supine position and underwent a contrast-enhanced computed tomography (CT) scan with 5 mm slices from cricoid cartilage to mid-abdomen. The image data sets were transferred to the RayStation planning system (Raysearch Radiation Oncology Systems). Gross tumor volume (GTV) included the primary tumor and suspicious lymph nodes (confirmed by histopathology after endobronchial/endoesophageal ultrasonography, with malignant features on CT scan, and/or fluorodeoxyglucose-- positron emission tomography positive). Clinical target volumes (CTVs) enclosed the GTV of the primary tumor and lymph nodes with 8-mm and 5-mm margins, respectively. The internal target volume (ITV) was delineated from four-dimensional CT images, which involved assessing the CTV on expiratory-phase images and then registering the outline to the images to create a union of target contours enclosing all possible positions of the target. The planning target volume (PTV) was created by an isotropic 5 mm expansion of the CTV. Patients were treated on a Synergy linac (Elekta Ltd, Crawley, UK). The prescribed dose to the PTV was 60 Gy in 30 (once-daily) fractions using IMRT with seven to nine coplanar fields or volumetric modulated arc therapy (VMAT). Weekly online image-guided RT for setup verifi-cation was required. The dose of the OARs was set to meet the following constraints: lung dose \<15 Gy, *V*~20~ \<30%; spinal cord, maximum dose \<45 Gy; heart, *V*~30~ \<40%; and esophagus, maximum dose \<66 Gy.

Esophageal contours, grouping, and dosimetric data
--------------------------------------------------

For each patient, the esophagus was delineated using the external esophageal contour from the cricoid cartilage to the gastroesophageal junction on the window of the planning CT scan (window width: 250--350 Hu; window level: 30--50 Hu). The esophagus was further divided into four subsites according to the seventh edition of the American Joint Committee on Cancer/Union for International Cancer Control (UICC) TNM staging system for esophageal carcinoma as follows: 1) the cervical esophagus was contoured from the cricoid cartilage to the sternal notch plane; 2) the upper thoracic esophagus was contoured from the sternal notch plane to the lower edge of the azygos vein; 3) the middle thoracic esophagus was contoured from the lower edge of the azygos vein to the lower pulmonary veins; and 4) the lower thoracic esophagus was contoured from the lower pulmonary veins to the gastroesophageal junction ([Figure 1](#f1-ott-11-6167){ref-type="fig"}). Patients were classified into four subgroups according to the subsite of the maximum mean dose, defined as the cervical esophagus group, upper thoracic esophagus group, middle thoracic esophagus group, and lower thoracic esophagus group, respectively.

For consistency, the esophagus was redelineated in all patients by the same radiation therapist. DVHs were then generated. The esophageal dosimetric parameters of the entire esophagus and subsites were extracted from the dose data set in the treatment-planning system including volume, mean dose, and the percentage of the volume of esophagus receiving 10 Gy (*V*~10~) to 60 Gy (*V*~60~) ([Figure S1](#SD1-ott-11-6167){ref-type="supplementary-material"}).

Toxicity scoring
----------------

The end point was defined as AE grade ≥2 (AE2+) during or at 3 months after RT treatment. AE was assessed weekly according to CTCAE V5.0. Toxicities were recorded as maximum grade at any point during treatment or in the follow-up period.

Statistical analyses
--------------------

Patient characteristics as well as clinical and dosimetric variables were summarized by descriptive statistics. One-way ANOVA with least significant difference was performed for analysis among the four subgroups. Univariate analyses were used to identify the significant risk factors among age (dichotomized by 60), Karnofsky Performance Status score (dichotomized by 90), gender, smoking history, pathology, tumor stage (dichotomized by T3), lymph node stage (dichotomized by N3), chemotherapy, maximum irradiated position, and dosimetric parameters, including mean dose and volumetric metrics. Because of the large intervariable correlation within the dosimetric variables, only one of the dosimetric variables was included in the pairs for each multivariable analysis. The Akaike information criterion (AIC) and Bayesian information criterion (BIC) were used for multivariable model selection, which balanced the goodness of fit of the model. The preferred model was chosen as the one resulting in the lowest AIC and BIC values. *P*\<0.05 was considered as statistically significant. Statistical programming was performed using SPSS 24.0 software.

Results
=======

Patient characteristics and clinical and dosimetric variables are summarized in [Table 1](#t1-ott-11-6167){ref-type="table"}. Of 193 patients treated with (chemo)radiotherapy, 90% received a platinum-containing regimen. AE was scored as grade 1 in 92 (47.7%) patients, as grade 2 in 44 (22.8%) patients, and as grade 3 in nine (4.7%) patients. No grade 4 or 5 AE was observed. The incidence of AE2+ in the cervical esophagus group, upper thoracic esophagus group, middle thoracic esophagus group, and lower thoracic esophagus group was 47.4% (9/19), 34.0% (18/53), 24.2% (22/91), and 13.3% (4/30), respectively. Baseline dosimetric characteristics were comparable between the four subgroups ([Table 2](#t2-ott-11-6167){ref-type="table"}).

Univariate logistic regression analysis revealed a significant increase in females, those with N3 stage, and those receiving concurrent chemotherapy. There was no statistical difference between the IMRT and VMAT (*P*\>0.05). All dosimetric parameters, including mean dose, all relative volumetric variables, and maximum radiation positions, were significant (*P*\<0.05; [Table 3](#t3-ott-11-6167){ref-type="table"}). N stage was not analyzed in the multivariate logistic regression model because it was highly associated with dosimetric parameters, which in turn correlated with esophagitis. Regarding the Spearman self-correlation matrix for the dosimetric variables, all variables were significantly correlated. An ANOVA analysis did not show any associations between gender, CCRT, position parameter, and dosimetric variables.

Each multivariate logistic regression model contained four independent variables: gender, CCRT, position parameter, and one of the dosimetric variables including mean dose and *V*~10~--*V*~60~. Gender, CCRT, maximum radiation position, and all the dosimetric variables demonstrated a significant correlation with AE2+ in all test models ([Table S1](#SD2-ott-11-6167){ref-type="supplementary-material"}). Goodness of fit was estimated by AIC and BIC values. The model with mean dose showed lower AIC and BIC values than models with other dosimetric variables ([Table 4](#t4-ott-11-6167){ref-type="table"}). We decided to include mean dose in the modeling procedure. The regression ORs for the optimal model indicated that patients had an increased risk of AE2+ with female (OR=2.47, *P*=0.014), with increasing mean dose (OR=1.33, *P*\<0.001), when they received CCRT (OR=3.67, *P*=0.015), or with the maximum radiation position in the upper part of the esophagus (OR=1.65, *P*=0.016; [Table 5](#t5-ott-11-6167){ref-type="table"}).

Discussion
==========

We constructed a multivariate model for AE2+ in patients with advanced-stage NSCLC treated with intensity-modulated (chemo)radiotherapy. Gender, CCRT, maximum radiation position, and mean dose were significantly associated with AE2+. Patients may be more sensitive to AE in the upper part of the esophagus in comparison with that in the lower part of the esophagus, which may contribute to a high risk of AE in patients with cervical lymph node metastases.

Research has shown that higher grade AE is the consequence of the accumulative effect of both chemotherapy and RT.[@b4-ott-11-6167],[@b5-ott-11-6167],[@b24-ott-11-6167] Meta-analysis of Gong et al[@b25-ott-11-6167] showed that patients receiving CCRT have an approximately fivefold increase in the risk of AE compared with those receiving sequential chemoradiotherapy (SCRT). The reason may be that cisplatin hampers the repair of DNA damage caused by the irradiation in esophageal epithelial cells. In some IMRT-based studies, CCRT was reported to result in a 27%--38% rate of grade 2 AE and an 8%--22% rate of grade 3 AE.[@b19-ott-11-6167],[@b24-ott-11-6167],[@b26-ott-11-6167],[@b27-ott-11-6167] In our study, the incidences of grade 2 and 3 AEs were 23.7% and 5.1%, respectively. The possible reason for the lower incidence is that the median RT dose was mostly 66 Gy in the other studies, whereas it was 60 Gy in ours.

Increased nodal stage has been identified as a predictor of AE. A relevant study pointed out that it is most likely a surrogate for larger tumor volumes and radiation fields.[@b28-ott-11-6167] Most studies have shown that N3 is closely related to the incidence of AE.[@b6-ott-11-6167],[@b7-ott-11-6167] However, Uterlinde et al suggested that nodal stage is not correlated with tumor volume but that involved mediastinal nodes have more clinical significance.[@b24-ott-11-6167] Therefore, N2--3 was selected for our analysis because of its increased correlation with mediastinal lymph nodes compared with N3. Gender was reported only occasionally in related studies.[@b29-ott-11-6167],[@b30-ott-11-6167] We found that female was statistically associated with esophagitis.

Various dosimetric parameters have shown a strong correlation with AE.[@b11-ott-11-6167]--[@b16-ott-11-6167],[@b31-ott-11-6167],[@b32-ott-11-6167] However, these results were mostly based on 3D-CRT. The hypothesis that the toxicity prediction models of 3D-CRT are not suitable for predicting toxicity after IMRT was supported. In our study, the mean dose showed a better goodness of fit in the multivariate model. The relevant study by Wijsman et al[@b26-ott-11-6167] also demonstrated that the mean dose was a good predictor of AE.

To the best of our knowledge, this is the second study suggesting the position parameter as related to AE. Pan et al[@b20-ott-11-6167] proposed that the upper part of the esophagus is more sensitive to injuries because of the different distributions of the sensory axons.[@b33-ott-11-6167] We divided the esophagus into four sub-sites according to physiological and anatomical structures. We found that the risk of AE in the upper esophagus was higher compared with that in the lower esophagus. Another possible reason is that the physiological structures of different parts of the esophagus are different. The epidermis of the upper esophageal mucous layer consists of squamous epithelial cells, and the muscularis consists of striated muscle. The epidermis of the lower esophageal mucous layer consists of columnar epithelial cells, and the muscularis consists of smooth muscle. The middle esophagus is a mixture of two different tissues above.[@b34-ott-11-6167] This conclusion also suggests the importance of personalized sparing of esophageal dose. The esophagus is adjacent to the OARs, including lungs, spinal cord, and heart in the RT plan of NSCLC patients. In some cases, such as where the radiation field is large or the shape of the tumor is irregular, it is often difficult to simultaneously limit the dose of the whole esophagus and all other OARs. The esophagus may even be exposed to over radiation to meet the PTV-planning constraints. However, we found that the irradiation field often does not cover the entire esophagus in patients with advanced-stage NSCLC. A total of 80.3% of the cases had at least one part of the esophagus exposed to little or no radiation in this study (*V*~10~=0 Gy). If we can limit only the part of the esophagus covered in the radiation field, the concept of personalized treatment can be achieved. This finding also suggests that there may be differences in the optimal sparing dose for different parts of the esophagus. Moreover, patients with cervical lymph node metastases should be aware of the high risk of AE.

There are still many deficiencies in this study. First, single-center research may lead to regional bias. The model still requires internal and external validation. Second, the evaluation of AE was mainly reported by patients, which may result in deviation of the incidence of esophagitis. Furthermore, the CTCAE score is essentially variable. There is currently a lack of more objective and rigorous criteria to evaluate normal tissue complications. Third, using DVH parameters may result in loss of spatial dosimetric information and may also ignore the movements of esophagus. Currently available studies have attempted to evaluate the effectiveness of other 3D dosimetric parameters (such as the surface dose of esophagus).[@b35-ott-11-6167]

Conclusion
==========

The most relevant prognostic variables in the multivariable model in patients with advanced-stage NSCLC undergoing intensity-modulated (chemo)radiotherapy are gender, concurrent chemotherapy, maximum radiation position, and mean dose. The sensitivity of AE varies in different parts of the esophagus. Validation in a large independent patient cohort is still warranted.
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###### 

Dose-volume histogram for four subgroups as the cervical esophagus (**A**), the upper thoracic esophagus (**B**), the mid-thoracic esophagus (**C**), and the lower thoracic esophagus (**D**).

**Note:** The colors of the curves representing different irradiation areas of esophagus are shown in [Figure 1](#f1-ott-11-6167){ref-type="fig"}.

###### 

Results of multivariate analyses

                                                                 Parameters                                                            OR (95% CI)                                           *P*-value
  -------------------------------------------------------------- --------------------------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------
                                                                                                                                                                                             
  Model 1                                                        Gender (female vs male[a](#tfn12-ott-11-6167){ref-type="table-fn"})   2.39 (1.17, 4.88)                                     0.016[b](#tfn13-ott-11-6167){ref-type="table-fn"}
  CCRT (yes vs no[a](#tfn12-ott-11-6167){ref-type="table-fn"})   3.35 (1.20, 9.35)                                                     0.021[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  Maximum radiation position (per 1 subsite upper)               1.64 (1.10, 2.44)                                                     0.015[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  *V*~10~ (per 10% increase)                                     1.35 (1.11, 1.64)                                                     0.003[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  Model 2                                                        Gender (female vs male[a](#tfn12-ott-11-6167){ref-type="table-fn"})   2.30 (1.12, 4.73)                                     0.023[b](#tfn13-ott-11-6167){ref-type="table-fn"}
  CCRT (yes vs no[a](#tfn12-ott-11-6167){ref-type="table-fn"})   3.32 (1.19, 9.29)                                                     0.022[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  Maximum radiation position (per 1 subsite upper)               1.64 (1.03, 2.30)                                                     0.037[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  *V*~20~ (per 10% increase)                                     1.35 (1.13, 1.60)                                                     0.001[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  Model 3                                                        Gender (female vs male[a](#tfn12-ott-11-6167){ref-type="table-fn"})   2.27 (1.11, 4.69)                                     0.026[b](#tfn13-ott-11-6167){ref-type="table-fn"}
  CCRT (yes vs no[a](#tfn12-ott-11-6167){ref-type="table-fn"})   3.86 (1.33, 11.14)                                                    0.013[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  Maximum radiation position (per 1 subsite upper)               1.50 (1.02, 2.24)                                                     0.045[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  *V*~30~ (per 10% increase)                                     1.38 (1.16, 1.63)                                                     \<0.001[b](#tfn13-ott-11-6167){ref-type="table-fn"}   
  Model 4                                                        Gender (female vs male[a](#tfn12-ott-11-6167){ref-type="table-fn"})   2.36 (1.14, 4.88)                                     0.020[b](#tfn13-ott-11-6167){ref-type="table-fn"}
  CCRT (yes vs no[a](#tfn12-ott-11-6167){ref-type="table-fn"})   3.93 (1.36, 11.32)                                                    0.011[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  Maximum radiation position (per 1 subsite upper)               1.56 (1.05, 2.34)                                                     0.029[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  *V*~40~ (per 10% increase)                                     1.37 (1.16, 1.61)                                                     \<0.001[b](#tfn13-ott-11-6167){ref-type="table-fn"}   
  Model 5                                                        Gender (female vs male[a](#tfn12-ott-11-6167){ref-type="table-fn"})   2.43 (1.18, 5.01)                                     0.016[b](#tfn13-ott-11-6167){ref-type="table-fn"}
  CCRT (yes vs no[a](#tfn12-ott-11-6167){ref-type="table-fn"})   3.88 (1.35, 11.15)                                                    0.012[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  Maximum radiation position (per 1 subsite upper)               1.70 (1.13, 2.54)                                                     0.011[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  *V*~50~(per 10% increase)                                      1.37 (1.16, 1.63)                                                     \<0.001[b](#tfn13-ott-11-6167){ref-type="table-fn"}   
  Model 6                                                        Gender (female vs male[a](#tfn12-ott-11-6167){ref-type="table-fn"})   2.32 (1.12, 4.81)                                     0.024[b](#tfn13-ott-11-6167){ref-type="table-fn"}
  CCRT (yes vs no[a](#tfn12-ott-11-6167){ref-type="table-fn"})   5.04 (1.61, 15.75)                                                    0.005[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  Maximum radiation position (per 1 subsite upper)               1.99 (1.29, 3.07)                                                     0.002[b](#tfn13-ott-11-6167){ref-type="table-fn"}     
  *V*~60~ (per 10% increase)                                     1.58 (1.25, 1.97)                                                     \<0.001[b](#tfn13-ott-11-6167){ref-type="table-fn"}   

**Notes:**

Reference category.

Statistically significant. *V*~10~--*V*~60~, percentage of esophageal volume receiving at least 10--60 Gy.

**Abbreviation:** CCRT, concurrent chemoradiotherapy.

**Disclosure**

The authors report no conflicts of interest in this work.

CCRT

:   concurrent chemoradiotherapy

AE

:   acute esophagitis

NSCLC

:   non-small-cell lung cancer

RTOG

:   Radiation Therapy Oncology Group

CTCAE

:   Common Toxicity Criteria for Adverse Events

3D-CRT

:   three-dimensional conformal radiotherapy

IMRT

:   intensity-modulated radiotherapy

OARs

:   organs at risk

UICC

:   Union for International Cancer Control

GTV

:   gross tumor volume

CTV

:   clinical target volume

ITV

:   internal target volume

PTV

:   planning target volume

DVHs

:   dose--volume histograms

SCRT

:   sequential chemoradiotherapy.

![Sagittal section illustrating delineation of the cervical esophagus (pink), the upper thoracic esophagus (purple), the mid-thoracic esophagus (orange), and the lower thoracic esophagus (yellow).](ott-11-6167Fig1){#f1-ott-11-6167}

###### 

Patient characteristics and clinical and dosimetric variables (N=193)

  Characteristics                       Median (range) or n (%)
  ------------------------------------- -------------------------
  Gender                                
  Male                                  136 (70.5)
  Female                                57 (29.5)
  **Age (years)**                       
  ≥60                                   101 (52.3)
  \<60                                  92 (47.7)
  **Smoking**                           
  Never and former smokers              112 (58.0)
  Current smoker                        81 (42.0)
  **Pathology**                         
  SCC                                   114 (59.1)
  NSCC                                  79 (40.9)
  **KPS**                               
  ≥90                                   135 (69.9)
  \<90                                  58 (30.1)
  **Clinical stage**                    
  IIA                                   14 (7.3)
  IIB                                   32 (16.6)
  IIIA                                  71 (36.8)
  IIIB                                  65 (33.7)
  IIIC                                  11 (5.7)
  **Tumor stage**                       
  T1                                    26 (13.5)
  T2                                    67 (34.7)
  T3                                    74 (38.3)
  T4                                    26 (13.3)
  **Lymph node stage**                  
  N0                                    21 (10.9)
  N1                                    52 (26.9)
  N2                                    92 (47.7)
  N3                                    28 (14.5)
  **Chemotherapy**                      
  Concurrent                            147 (76.2)
  Sequential                            35 (18.1)
  None                                  11 (5.7)
  **Type of concurrent chemotherapy**   
  Cisplatin+etoposide                   51 (34.7)
  Cisplatin+docetaxel                   42 (28.6)
  Cisplatin+pemetrexed                  37 (25.2)
  Carboplatin+docetaxel                 15 (10.2)
  Other/not specified                   2 (1.4)
  **Type of sequential chemotherapy**   
  Cisplatin+pemetrexed                  10 (28.6)
  Cisplatin+docetaxel                   19 (54.3)
  Others/not specified                  6 (17.1)
  **RT**                                
  IMRT                                  152 (78.8)
  VMAT                                  41 (21.2)
  **RT dose**                           
  ≥60 Gy                                102 (52.8)
  \<60 Gy                               91 (47.2)
  Volume of esophagus (cc)              30.7 (5.5, 56.3)
  Esophagus *V*~10~ (%)                 46.8 (8.3, 92.9)
  Esophagus *V*~20~ (%)                 40.0 (0, 90.8)
  Esophagus *V*~30~ (%)                 34.5 (0, 87.9)
  Esophagus *V*~40~ (%)                 27.1 (0, 86.2)
  Esophagus *V*~50~ (%)                 17.6 (0, 84.2)
  Esophagus *V*~60~ (%)                 5.4 (0, 71.8)
  Mean dose to esophagus (Gy)           20.9 (2.5, 56.1)

**Note:** All staging data refer to UICC, eighth edition.

**Abbreviations:** IMRT, intensity-modulated radiotherapy; KPS, Karnofsky Performance Status; NSCC, non-squamous cell carcinoma; RT, radiotherapy; SCC, squamous cell carcinoma; UICC, Union for International Cancer Control; *V*~10~--*V*~60~, percentage of esophageal volume receiving at least 10--60 Gy; VMAT, volumetric modulated arc therapy.

###### 

Dosimetric variables in four subgroups

                                   Cervical esophagus    Upper thoracic esophagus   Middle thoracic esophagus   Lower thoracic esophagus   *P*-value
  -------------------------------- --------------------- -------------------------- --------------------------- -------------------------- ---------------------------------------------------
  Vol (cc), median (range)         5.9 (3.6, 13.3)       6.9 (2.6, 12.6)            8.1 (3.4, 20.3)             9.8 (5.6, 13.9)            \<0.01[a](#tfn3-ott-11-6167){ref-type="table-fn"}
  *V*~10~ (%), median (range)      100.0 (43.2, 100.0)   100.0 (42.0, 100.0)        99.0 (30.8, 100.0)          100.0 (31.8, 100.0)        0.125
  *V*~20~ (%), median (range)      100.0 (31.8, 100.0)   100.0 (11.0, 100.0)        87.3 (4.2, 100.0)           100.0 (0, 100.0)           0.054
  *V*~30~ (%), median (range)      97.9 (21.9, 100.0)    92.2 (0, 100.0)            76.6 (0, 100.0)             100.0 (0, 100.0)           0.186
  *V*~40~ (%), median (range)      85.5 (17.8, 100.0)    76.0 (0, 100.0)            66.7 (0, 100.0)             83.4 (0, 100.0)            0.356
  *V*~50~ (%), median (range)      58.6 (9.8, 100.0)     37.6 (0, 100.0)            49.4 (0, 100.0)             66.4 (0, 100.0)            0.199
  *V*~60~ (%), median (range)      13.0 (0, 42.3)        4.1 (0, 98.6)              14.6 (0, 94.9)              27.5 (0, 100.0)            0.059
  Mean dose (Gy), median (range)   46.8 (23.1, 56.8)     45.2 (12.3, 64.4)          45.9 (9.83, 62.8)           42.9 (10.3, 63.1)          0.122

**Notes:**

Statistically significant. Patients were classified into four subgroups according to the maximum irradiated site. *V*~10~--*V*~60~, percentage of esophageal volume receiving at least 10--60 Gy; Vol, volume of esophagus.

###### 

Univariate logistic regression analysis of factors associated with the development of grade ≥2 AE

  Parameters                                                                                        OR (95% CI)         *P*-value
  ------------------------------------------------------------------------------------------------- ------------------- ----------------------------------------------------
                                                                                                                        
  **Patient characteristics**                                                                                           
  Age (≥60 years vs \<60 years[a](#tfn4-ott-11-6167){ref-type="table-fn"})                          1.12 (0.61, 2.09)   0.711
  Gender (female vs male[a](#tfn4-ott-11-6167){ref-type="table-fn"})                                2.27 (1.18, 4.37)   0.014[b](#tfn5-ott-11-6167){ref-type="table-fn"}
  KPS (KPS ≥90 vs KPS \<90[a](#tfn4-ott-11-6167){ref-type="table-fn"})                              1.15 (0.58, 2.27)   0.698
  Pathology (SCC vs NSCC[a](#tfn4-ott-11-6167){ref-type="table-fn"})                                0.76 (0.41, 1.42)   0.392
  Smoking (current smoker vs never and former smokers[a](#tfn4-ott-11-6167){ref-type="table-fn"})   1.85 (0.99, 3.46)   0.053
  Tumor stage (T3--4 vs T1--2[a](#tfn4-ott-11-6167){ref-type="table-fn"})                           0.76 (0.41, 1.42)   0.391
  Lymph node stage (N2--3 vs N0--1[a](#tfn4-ott-11-6167){ref-type="table-fn"})                      2.67 (1.32, 5.41)   0.006[b](#tfn5-ott-11-6167){ref-type="table-fn"}
  **Treatment**                                                                                                         
  CCRT (yes vs no[a](#tfn4-ott-11-6167){ref-type="table-fn"})                                       3.54 (1.41, 8.91)   0.007[b](#tfn5-ott-11-6167){ref-type="table-fn"}
  SCRT (yes vs no[a](#tfn4-ott-11-6167){ref-type="table-fn"})                                       0.79 (0.35, 1.82)   0.585
  RT (IMRT vs VMAT[a](#tfn4-ott-11-6167){ref-type="table-fn"})                                      1.18 (0.55, 2.56)   0.669
  **Dosimetric variables**                                                                                              
  Volume of esophagus (per 5 cc increase)                                                           0.96 (0.80, 1.15)   0.641
  *V*~10~ (per 10% increase)                                                                        1.34 (1.12, 1.60)   0.001[b](#tfn5-ott-11-6167){ref-type="table-fn"}
  *V*~20~ (per 10% increase)                                                                        1.37 (1.17, 1.61)   \<0.001[b](#tfn5-ott-11-6167){ref-type="table-fn"}
  *V*~30~ (per 10% increase)                                                                        1.39 (1.19, 1.62)   \<0.001[b](#tfn5-ott-11-6167){ref-type="table-fn"}
  *V*~40~ (per 10% increase)                                                                        1.36 (1.17, 1.58)   \<0.001[b](#tfn5-ott-11-6167){ref-type="table-fn"}
  *V*~50~ (per 10% increase)                                                                        1.33 (1.13, 1.56)   \<0.001[b](#tfn5-ott-11-6167){ref-type="table-fn"}
  *V*~60~ (per 10% increase)                                                                        1.35 (1.10, 1.65)   0.004[b](#tfn5-ott-11-6167){ref-type="table-fn"}
  Mean dose to esophagus (per 5 Gy increase)                                                        1.30 (1.13, 1.50)   \<0.001[b](#tfn5-ott-11-6167){ref-type="table-fn"}
  Maximum radiation position (per 1 subsite upper)                                                  1.74 (1.19, 2.54)   0.004[b](#tfn5-ott-11-6167){ref-type="table-fn"}

**Notes:**

Reference category.

Statistically significant. *V*~10~--*V*~60~, percentage of esophageal volume receiving at least 10--60 Gy.

**Abbreviations:** AE, acute esophagitis; CCRT, concurrent chemoradiotherapy; IMRT, intensity-modulated radiotherapy; KPS, Karnofsky Performance Status; NSCC, non-squamous cell carcinoma; RT, radiotherapy; SCC, squamous cell carcinoma; SCRT, sequential chemoradiotherapy; UICC, Union for International Cancer Control; VMAT, volumetric modulated arc therapy.

###### 

AIC of the models

  Dosimetric parameters   AIC      BIC      Logarithmic likelihood ratio
  ----------------------- -------- -------- ------------------------------
  *V*~10~                 115.60   161.27   87.60
  *V*~20~                 123.97   172.91   93.97
  *V*~30~                 116.18   161.86   88.18
  *V*~40~                 122.85   168.53   94.85
  *V*~50~                 119.67   165.35   92.67
  *V*~60~                 130.83   183.03   98.83
  Mean dose               98.09    140.50   72.09

**Notes:** All models included four variables: gender, concurrent chemotherapy, maximum radiation position, and one of above dosimetric parameters. *V*~10~--*V*~60~, percentage of esophageal volume receiving at least 10--60 Gy.

**Abbreviations:** AIC, Akaike information criterion; BIC, Bayesian information criterion.

###### 

Multivariate logistic regression analysis of factors associated with the development of grade ≥2 AE

  Parameters                                                           OR (95% CI)          *P*-value
  -------------------------------------------------------------------- -------------------- -----------------------------------------------------
  Gender (female vs male[a](#tfn9-ott-11-6167){ref-type="table-fn"})   2.47 (1.20, 5.09)    0.014[b](#tfn10-ott-11-6167){ref-type="table-fn"}
  CCRT (yes vs no[a](#tfn9-ott-11-6167){ref-type="table-fn"})          3.67 (1.29, 10.48)   0.015[b](#tfn10-ott-11-6167){ref-type="table-fn"}
  Maximum radiation position (per 1 subsite upper)                     1.65 (1.10, 2.48)    0.016[b](#tfn10-ott-11-6167){ref-type="table-fn"}
  Mean dose to esophagus (per 5 Gy increase)                           1.33 (1.14, 1.55)    \<0.001[b](#tfn10-ott-11-6167){ref-type="table-fn"}

**Notes:**

Reference category.

Statistically significant.

**Abbreviations:** AE, acute esophagitis; CCRT, concurrent chemoradiotherapy.
